Education

• B.S: Florida International University, Physics, 2002
• Ph.D: Florida International University, Particle Physics, 2009

Postdoctoral Fellowship

2009-2012: Massachusetts General Hospital & Harvard Medical School, Medical Physics

Areas of Interest

• Proton therapy
• Image-guided radiotherapy

Publications

• Schmidt DR, Bhagwat M, Glazer DI, Chen MH, Moteabbed M, McMahon E, Loffredo MJ, Tempany CM, D'Amico AV. MRI-Based Radiotherapy Planning to Reduce Rectal Dose in Excess of Tolerance. Prostate Cancer. 2022;2022:7930744.
• Marin T, Zhuo Y, Lahoud RM, Tian F, Ma X, Xing F, Moteabbed M, Liu X, Grogg K, Shusharina N, Woo J, Lim R, Ma C, Chen YE, El Fakhri G. Deep learning-based GTV contouring modeling inter- and intra- observer variability in sarcomas. Radiother Oncol. 2022;167:269-276.
• Moteabbed M, Smeets J, Hong TS, Janssens G, Labarbe R, Wolfgang JA, Bortfeld TR. Toward MR-integrated proton therapy: modeling the potential benefits for liver tumors. Phys Med Biol. 2021 Sep 23;66(19).
• Lucconi G, Bentefour EH, Samuel D, Weaver K, Moteabbed M, Lu H-M. In-vivo proton range verification for reducing the risk of permanent alopecia in medulloblastoma treatment. Rad Med Protect, 2021;2(3): 95-102.
• Moteabbed M, Harisinghani M, Paganetti H, Trofimov A, Lu HM, Efstathiou JA. Proton vs. photon radiotherapy for MR-guided dose escalation of intraprostatic lesions. Acta Oncol. 2021;60(10):1283-1290.
• Hoffmann A, Oborn B, Moteabbed M, Yan S, Bortfeld T, Knopf A, Fuchs H, Georg D, Seco J, Spadea MF, Jäkel O, Kurz C, Parodi K. MR-guided proton therapy: a review and a preview. Radiat Oncol. 2020;15(1):129.
• Moteabbed M, Trofimov A, Khan FH, et al. Impact of interfractional motion on hypofractionated pencil beam scanning proton therapy and VMAT delivery for prostate cancer. 2018;Med. Phys. 45(9):4011–4019.
• Moteabbed M, Trofimov A, Sharp GC, et al. Proton therapy of prostate cancer by anterior oblique beams: implications of setup and anatomy variations. Phys. Med. Biol. 2017;62(5):1644–960. (Featured in MedicalPhysicsWeb)
• Underwood TSA, Voog JC, Moteabbed M, et al. Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams. Acta Oncol. 2017;56(4):575–9581.
• Hoesl M., Samuel D., Moteabbed M., et al.  Clinical commissioning of an in-vivo range verification system for prostate cancer treatment with anterior and anterior oblique proton beams. Phys. Med. Biol., 2016;61(8):3049–962.
•  Geng C., Moteabbed M., Seco J., Gao Y., Xu X., Ramos-Mendez J., Faddegon B., Paganetti H. Risk assessment for the fetus considering scattered and secondary radiation from photon and proton therapy when treating a brain tumor of the mother. Phys. Med. Biol., 2016;61(2):683–95. (Featured in MedicalPhysicsWeb)
• Moteabbed M., Yock T.I., Depauw N., Madden T.M., Kooy H.M., Paganetti H., Impact of spot size and beam-shaping devices on the treatment plan quality for pencil beam scanning proton therapy. Int. J. Radiat. Oncol. Biol. Phys., 2016;95(1):190–9198.
• Underwood T., Diantsoudi D., Moteabbed M., Zietman A.L., Efstathiou J.A., Paganetti H., Lu H-M. Can we advance proton therapy for prostate? Considering alternative beam angles and RBE variations when comparing against IMRT. Int. J. Radiat. Oncol. Bio.l Phys., 2016;95(1):454–64.
• Geng C., Moteabbed M., Xie Y., Schuemann J, Yock T., Paganetti H. Assessing the radiation-induced second cancer risk in proton therapy for pediatric brain tumors: the impact of employing a patient-specific aperture in pencil beam scanning. Phys. Med. Biol., 2016;61(1):12–22.
• Moteabbed M., Trofimov A., Sharp G.C., Wang Y., Zietman A.L., Efstathiou J.A., Lu H-M. A prospective comparison of the effects of interfractional variations on proton therapy and IMRT for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2015;95(1):444–53.
• Schuemann J., Giantsoudi D., Grassberger C., Moteabbed M., Min C.H., Paganetti H. Assessing the clinical impact of approximations in analytical dose calculations for proton therapy. Int. J. Radiat. Oncol. Biol. Phys., 2015;92(5):1157–64.
• Nguyen J., Moteabbed M., Paganetti H. Assessment of uncertainties in radiation induced cancer risk predictions at clinically relevant doses. Med. Phys., 2015;42(1):81.
• Moteabbed M., Sharp G.C., Wang Y., Trofimov A., Efstathiou J. A., Lu H-M. Validation of a Deformable Image Registration Technique for Cone Beam CT-Based Dose Verification. Med. Phys., 2014;42(1):196.
• Ladra, M. M., Edgington, S. K., Mahajan, A., Grosshans, D., Szymonifka, J., Khan, F., Moteabbed M., Friedmann A. M., MacDonald S. M., Tarbell N. J. Yock T. I. A dosimetric comparison of proton and intensity modulated radiation therapy in pediatric rhabdomyosarcoma patients enrolled on a prospective phase II proton study. Radiother. Oncol., 2014;113(1):77–83.
• Moteabbed M., Schuemann J., Paganetti H. Dosimetric feasibility of real-time MRI-guided proton therapy. Med. Phys., 2014;41:111713.
• Moteabbed M., Yock T. I., and Paganetti H. The risk of radiation-induced second cancers in the high to medium dose region: a comparison between passive and scanned proton therapy, IMRT and VMAT for pediatric patients with brain tumors. Phys. Med. Biol., 2014;59:2883–99. (Featured in MedicalPhysicsWeb)
• Moteabbed M., Niroula M., Raue B. A., et al. Demonstration of a novel technique to measure two-photon exchange effects in elastic e±p scattering. Phys. Rev. C. 2013;88:025210. 
• Paganetti H., Athar B. S., Moteabbed M., Adams J. A., Schneider U., and Yock T. I. Assessment of radiation-induced second cancer risks in proton therapy and IMRT for organs inside the primary radiation field. Phys. Med. Biol., 2012;57:6047–61.
• Efstathiou J. A., Paly J. J., Lu H-M., Athar B. S., Moteabbed M., Niemierko A., Adams J. A., Bekelman J. E., Shipley W. U., Zietman A. L., and Paganetti H. Adjuvant radiation therapy for early stage seminoma: Proton versus photon planning comparison and modeling of second cancer risk. Radiother. Oncol., 2012;103:12–17.  
• Carabe A., Moteabbed M., Depauw N., Schuemann J., and Paganetti H. Range uncertainty in proton therapy due to variable biological effectiveness. Phys. Med. Biol., 2012;57:1159–72. (Featured in MedicalPhysicsWeb)
• Moteabbed M., Geyer A., Drenkhahn R., Bolch W. E., and Paganetti H. Comparison of whole-body phantom designs to estimate organ equivalent neutron doses for secondary cancer risk assessment in proton therapy. Phys. Med. Biol., 2012;57:499–515.
• Moteabbed M., España S., and Paganetti H. Monte Carlo patient study on the comparison of prompt gamma and PET imaging for range verification in proton therapy. Phys. Med. Biol., 2011;56, 1063–82.